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Edited by Felix WielandAbstract The glycerophosphoinositols are ubiquitous phospho-
inositide metabolites involved in the control of several cell func-
tions. They exert their actions both intracellularly and by rapidly
equilibrating across the plasma membrane when added to cells,
implying the existence of a transporter for their membrane
permeation. Such a transporter, GIT1, has been cloned in yeast.
By PSI-BLAST analysis, we have identiﬁed the Glut2 trans-
porter as a human-genome candidate ortholog of GIT1. This
was supported directly through the use of inhibitors, siRNAs
and competition studies of speciﬁc uptake of GroPIns in HeLa
cells over-expressing human Glut2. These data identify Glut2
as a GroPIns transporter in mammals, and deﬁne a physiologi-
cally relevant cell-permeation mechanism.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The glycerophosphoinositols are intracellular, water-soluble
phosphoinositide metabolites that are involved in the control
of signalling enzymes (e.g. adenylyl cyclase [1]), in actin cyto-
skeleton organization [2], in invasion of the extracellular
matrix by melanoma and breast carcinoma cell lines [3], and
in the control of cell proliferation in epithelial cells [4,5]. Of
these compounds, the most abundant in cells is glycerophos-
phoinositol (GroPIns), with its intracellular concentrations
generally ranging from 50 to 450 lM across diﬀerent normal
and transformed cell lines [5,6]. The intracellular accumulation
of this compound was originally correlated to the activation of
the Ras pathway [7,8] and to the diﬀerentiation/dediﬀerentia-
tion of several cell lines, including macrophages and hepato-
cytes [9–12].
In yeast, GroPIns is secreted as a product of phosphoinosi-
tide catabolism, and can be taken up from the extracellular
medium and incorporated into the phosphoinositides when*Corresponding authors. Fax: +39 0872 570412.
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doi:10.1016/j.febslet.2006.11.039the inositol supply is scarce or in phosphate-starved yeast cells
[13–17]. GroPIns is transported across the yeast plasma mem-
brane by a well-characterized mechanism that involves a
permease encoded by the 1556-bp GIT1 gene, which codes for
a 518-amino-acid protein with a predicted molecular mass of
57.3 kDa [16,17]. Gitlp contains the SDRIGR(K/R) sugar-
transport motif around amino acid 329 and 12 potential mem-
brane-spanning domains. Speciﬁcity studies have indicated that
GroPIns transport in yeast is not aﬀected by excess glycerol or
inositol, is inhibited by excess glycerol 3-phosphate, and is only
partially inhibited by excess glycerophosphocholine and glyc-
erophosphoethanolamine [16]. GIT1 expression and Gitlp
transport activity are induced in response to inositol depriva-
tion and phosphate deprivation [17]. The combination of Gitlp
and extracellular phospholipase activity, therefore, provide
yeast with the ability to obtain crucial nutrients (inositol and
phosphate) in environments in which phosphatidylinositol or
GroPIns are available. Although a similar mechanism has been
proposed for glycerophosphoinositol transport in mammalian
cells [2,18], no further information as to the molecular identity
or activity of this transporter has been provided to date.
It has previously been shown that GroPIns is present in both
intracellular and extracellular spaces [5,19], and that extracel-
lular GroPIns is a substrate of speciﬁc phosphodiesterases that
are able to hydrolyze it to inositol and glycerol phosphate [20].
As the phospholipase A2 and the lysolipase that are involved in
the formation of GroPIns are intracellular enzymes, our
hypothesis is that a speciﬁc transporter exists in mammals that
mediates both GroPIns uptake and exclusion, depending on the
GroPIns concentration gradient across the plasma membrane.
Under physiological conditions, this gradient could arise from
the intracellular formation of GroPIns following phospholi-
pase A2 activation [4,5]; alternatively, it could derive from the
exogenous application of GroPIns [2,3].
The understanding of the mechanism of transport of Gro-
PIns across the plasma membrane is thus relevant to the full
deﬁnition of its metabolism and mechanism of action. With
the aim of identifying the GroPIns transporter, we carried
out sequence analyses and biochemical studies, which have
led to the identiﬁcation of the permease Glut2 as the ﬁrst Gro-
PIns-speciﬁc transporter in mammalian cells.2. Materials and methods
2.1. Materials
Lipofectamine-plus reagent was from Invitrogen (Ontario, Canada).
Tetanolysin from Clostridium tetani, phloretin, fetal bovine serumblished by Elsevier B.V. All rights reserved.
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the actin polyclonal antibody were from Sigma (MO, USA). [3H] glu-
cosamine (196 Gbq/mmol, 5.3 Ci/mmol) was from Amersham Biosci-
ences (Buckinghamshire, UK). [3H] GroPIns was prepared from [3H]
L-a-phosphatidylinositol (Perkin–Elmer, Boston, USA), (314.5 Gbq/
mmol, 8.5 Ci/mmol) according to the deacylation procedure originally
reported by Clarke and Dawson [21]. GroPIns was from Euticals
S.p.A. (Lodi, Italy). All other reagents were of the highest purities
available and were obtained from GIBCO Brl (Grand Island, NY).2.2. Sequence analysis
The Gitlp sequence (accession number P25346) was compared with
mammalian sequences using PSI-BLAST. The ﬁrst iteration of PSI-
BLAST showed an e-value of 0.027, with an 18% identity and a 33%
similarity in an alignment comprising amino acids 84–475 of yeast
Gitlp. The global alignment of yeast Gitlp and human Glut2 (hGlut2)
was done with Clustal W, with a 13% score identity. The search of the
phylogenetic patterns via the identiﬁcation of common Eukaryotic
Orthologous Groups (KOGs) was carried out with the NCBI CDD
(Conserved Domain Database), and showed that yeast Gitlp and
hGlut2 aligned signiﬁcantly with: (i) the permease of the major facili-
tator superfamily (KOG0569), with e-values of 2 · e7 and 1 · e125,
respectively; (ii) the predicted transporter (major facilitator superfam-
ily) (KOG0254), with e-values of 5 · e15 and 4 · e60, respectively;
(iii) the synaptic vesicle transporter SVOP and related transporters
(major facilitator superfamily) (KOG0255), with e-values of 1 · e7
and 1 · e18, respectively; and (iv) the inorganic phosphate transporter
(KOG0252), with e-values of 2 · e130 and 2 · e12, respectively.2.3. Cell culture and transfection
HeLa cells were transfected with 8 lg cDNA/petri dish using the
Lipofectamine-plus method, according to the manufacturer instruc-
tions. Human Glut2 transporter cDNA (1760 bp), generously provided
by G.I. Bell (Howard Hughes Medical Institute, Chicago, USA), was
subcloned in the pCMV4 expression vector (Invitrogen, CA, USA).
The transfection eﬃciency, evaluated by immunoﬂuorescence analysis
(see below), was 20%. Cytosol and membrane preparations were
obtained according to Garcia-Higueras et al. [22]. Glut2 expression
was veriﬁed by Western blotting, using rabbit antiserum against
hGlut2 (1:1000) (Alpha Diagnostic, TX, USA), and by immunoﬂuo-
rescence analysis, with the same antiserum (1:100), as previously
reported [2].2.4. GroPIns uptake assay
HeLa cells were scraped from the petri dishes, and a fraction was
used for counting and for a trypan blue vitality test. Vitality was
always more than 95%. Two ·106 cells/sample were resuspended in
150 ll buﬀer A (cell medium in which the cells had grown for at least
4 h, plus 25 mM HEPES, pH 7.4). The cellular uptake assays were
initiated by adding this to 150 ll buﬀer A containing GroPIns or
glucosamine, to give the ﬁnal concentrations indicated, and the [3H]
GroPIns (8.5 Ci/mmol; 400000 cpm) or [3H] glucosamine (5.3 Ci/
mmol 40000 cpm) tracers, as appropriate. Where necessary, the
osmolarity was corrected by inclusion of NaCl. The cells were then
either ﬁltered directly (see below; for the time zero background) or
incubated for the times indicated in a 37 C water bath under gentle
shaking. The uptake was terminated by applying the cells onto nitro-
cellulose ﬁlters (Whatman, NJ, USA) on a vacuum-ﬁlter apparatus,
followed by 3 · 1 ml washes with ice-cold buﬀer B (unlabelled GroPIns
or glucosamine at the same concentration used during the uptake
assays, plus 0.3% BSA, 1 mM HgCl2 in PBS, pH 7.4); the ﬁlters were
then dissolved in Filter Count scintillant (Perkin–Elmer) and counted.
Cell lysates were obtained using four cycles of freezing in liquid N2
and thawing at 37 C in a water bath sonicator. Tetanolysin permeabi-
lization was performed with the procedure adapted from Riese et al.
[23].2.5. Glut2 RNAi
Glut2 sequence-speciﬁc silencing was performed in HEK293 cells
with Glut2 siRNA(h) duplexes (Santa Cruz Biotechnology Inc., SanDiego, CA, USA) and the siCONTROL non-targeting duplexes
(Dharmacon Inc., Lafayette, CO, USA) using the Oligofectamine
Reagent (Invitrogen) according to the manufacturer instructions. After
silencing, the cells were seeded in serum-free growth medium for 4 h,
then 10% FBS was added for a further 48 h before the uptake assays
and Western blotting.2.6. Statistical analysis
The data are expressed as means ± S.E. of three or four independent
experiments, with each performed in quadruplicate. Statistical analysis
was by Student’s t-test.3. Results
3.1. Identiﬁcation of a Gitlp human ortholog
The initial analysis of Gitlp, the GroPIns transporter of Sac-
charomyces cerevisiae, and the sequence comparison with
mammalian sequences by PSI-BLAST led to the identiﬁcation
of Glut2 as the closest human hit. Although the global align-
ment of the two sequences showed an identity of only 13%, a
search for clusters of orthologous groups (see Section 2) clearly
indicated that they belong to common clusters and that some
of the amino acids essential for the transporter functions are
conserved in both sequences (see Fig. 1).
Gitlp and Glut2 also share a similar structure, with sequence
analysis studies predicting that they include 12 membrane-
spanning helices (as underlined in Fig. 1; [16,24]). In addition,
both proteins include the R(K/R)XGRR(K/R) motif in their
sequence, which is recognized as being speciﬁc for the major
facilitator superfamily (MFS) members (blue in Fig. 1; [16,24]).
The residues critical for the helix structure, including the gly-
cines of the transmembrane regions that are characteristic of
the Glut family, have been shown to be required for trans-
porter function [24], and they are conserved in the Gitlp
sequence (Fig. 1). Other important motifs of the Glut trans-
porters that have been suggested to participate in substrate
recognition, such as the STSIF-motif in loop 7, were also
found in the Gitlp sequence (Fig. 1), whereas the QLS-motif
(QFS for hGlut2) was not present.
Altogether these data point to a number of similarities
between the Gitlp and Glut2 proteins, which led us to further
investigate the transporter function of Glut2.3.2. Glut2 over-expression in HeLa cells
To determine whether hGlut2 represents the mammalian
counterpart of yeast Gitlp, we measured the uptake of
GroPIns in HeLa cells over-expressing hGlut2. The mammalian
expression vector carrying hGlut2 cDNA (hGlut2/pCMV4), or
the vector alone (pCMV4, as mock), were transfected into
HeLa cells, which do not endogenously express this
transporter, and 24 h later the cells were used in the GroPIns
uptake experiments. Human Glut2 over-expression and its
membrane localization were conﬁrmed by Western blotting
of cell lysates (Fig. 2A, left panel); two major bands of 57
and 59 kDa were speciﬁcally identiﬁed in GLUT2-transfected
HeLa cells. Both bands correspond to the Glut2 transporter,
but with diﬀerent levels of glycosylation or, possibly, other
post-translational modiﬁcations [25]. A third minor band at
a lower molecular weight (53 kDa) was recognized by the
speciﬁc antibody; this can be assigned to the degradation prod-
ucts of Glut2 as it was detected only in transfected cells. Imm-
Fig. 1. Sequence alignment of Gitlp and hGlut2. PSI-BLAST alignment of amino acids 84–475 of Gitlp (accession no. P25346) and 92–508 of hGlut2
(accession no. PI1168). As indicated, the alignment shows 81/433 (18%) common identities, 145/433 (33%) positives (+; semi-conserved residues that
have a positive score from the BLOSUM-62 matrix [35]), and 57/433 (13%) gaps. The highly conserved residues for the Glut family members are
highlighted in yellow, and the MFS-speciﬁc sequence motifs in blue [26]. The predicted membrane spanning helices (from helices 2 to 12) are
underlined.
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staining for the hGlut2 transporter in GLUT2-transfected cells
(Fig. 2B), which was absent in mock-transfected HeLa cells.
Since Glut2 has been reported to speciﬁcally transport
glucosamine [26], we veriﬁed the functionality of over-expressed
hGlut2 by evaluating glucosamine (500 lM) uptake. After
5 min of incubation at 37 C, the rate of glucosamine uptake
was over twofold higher in GLUT2-transfected cells, as
compared to mock-transfected cells (1.63 and 0.74 nmoles/
min/106 cells, respectively). Altogether these data indicate that
the over-expressed hGlut2 transporter correctly localizes at the
plasma membrane and that it functions in the glucosamine
uptake assays.
3.3. Characterization of GroPIns transport
GroPIns transport was evaluated by determining the time-
course and concentration dependence of GroPIns uptake in
GLUT2-transfected HeLa cells (see Section 2). As shown inFig. 2C, the GroPIns uptake (100 lM, 37 C) was rapid (with-
in 1 min reaching 75% of that seen at 15 min) and signiﬁ-
cantly higher than in the mock-transfected HeLa cells.
Similar time-course assays were performed with HEK293
cells, which endogenously express the hGlut2 transporter
(Fig. 2A, right panel). The extent of GroPIns uptake observed
at 37 C is reported in Fig. 2D, and it is compatible with the
proposal that endogenously expressed Glut2 can function as
a GroPIns transporter.
To determine whether a fraction of GroPIns was bound to
membranes (rather than internalized), we used two diﬀerent
approaches. In the ﬁrst, total GroPIns ‘‘uptake’’ measured in
intact cells was compared with the [3H] GroPIns associated
with cell lysates. In Fig. 3A, the diﬀerence in total cell-associ-
ated [3H] GroPIns between the intact and lysed cells (40% for
mock-transfected cells and 370% for GLUT2-transfected cells)
represents the GroPIns uptake, with the diﬀerence between the
uptake in mock- and GLUT2-transfected intact cells indicating
Glut2 mock
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Fig. 2. Characterization of GroPIns transport. (A) Western blotting
with anti-hGlut2 antiserum shows speciﬁc bands in the membrane
preparation (M.) from GLUT2-transfected HeLa cells (left panel); and
in a plasma membrane preparation (M.) from HEK293 cells (right
panel). Cyt., cytosol. (B) Immunoﬂuorescence staining of GLUT2-
transfected HeLa cells with anti-hGlut2 antiserum, showing speciﬁc
staining at the plasma-membrane. (C) Time courses of GroPIns
(100 lM, 37 C) uptake in mock- and GLUT2-transfected HeLa cells,
expressed as dpm. Data are means ± S.E. from four independent
experiments, each performed in quadruplicate; a signiﬁcant increase in
uptake is seen, P < 0.02. (D) Time course of GroPIns (250 lM, 37 C)
uptake in HEK293 cells, expressed as dpm. Data are means ± S.E.
from four independent experiments, each performed in quadruplicate.
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This was also repeated in HEK293 cells, where the increase in
the GroPIns uptake was 474%, corresponding to 0.48 pm-
oles/min/106 cells (Fig. 3B).
The second approach involved the use of permeabilized cells,
where there is no signiﬁcant GroPIns uptake and the GroPIns
associated with the cells is bound to either membranes or other
cellular structures. In this case, GroPIns uptake (100 lM) with
time was determined while comparing intact cells and cells
permeabilized with tetanolysin (see Section 2; Fig. 3C). As
expected, the intact cells over-expressing the transporter
showed a clear increase in incorporated radioactivity, indicat-
ing uptake of GroPIns under these conditions. Moreover, the
permeabilized, GLUT2-transfected cells showed a slightlyhigher binding to the membrane compared to the permeabili-
zed mock-transfected cells, suggesting that over-expression of
the transporter per se can induce an increase in GroPIns bin-
ding to cellular membranes (Fig. 3C).
Similar experiments were performed in intact and tetanoly-
sin-permeabilized HEK293 cells. Again, a signiﬁcant diﬀerence
between intact and permeabilized HEK293 cells was seen with
time, demonstrating further that in cells endogenously express-
ing the hGlut2 transporter, it is indeed possible to measure
speciﬁc GroPIns uptake (Fig. 3D).
The apparent aﬃnity of hGlut2 for GroPIns was measured
in uptake experiments using 0.1–100 lM GroPIns, with mo-
ck- and GLUT2-transfected HeLa cells (Fig. 4). The GroPIns
uptake was concentration dependent, and the Km of 80 lM
was well within the intracellular concentration range of
GroPIns (Fig. 4) [6].
Altogether, these data indicate that the hGlut2 transporter
can mediate the uptake of GroPIns in diﬀerent cell types.3.4. Glucosamine competition, phloretin inhibition and RNAi
To further demonstrate that the incorporation of GroPIns
occurs through the Glut2 transporter, the eﬀects of potential
competitors, blockers and siRNAs were evaluated. First, both
mock- and GLUT2-transfected cells were incubated with
10 lM GroPIns in the absence and presence of glucosamine,
as detailed in Fig. 5A. Under these conditions, GroPIns uptake
was reduced by 35%.
The speciﬁcity of GroPIns uptake by the hGlut2 transporter
was then evaluated in competition assays using small mo-
lecules such as inositol and glucose. However, GroPIns uptake
at 37 C is very rapid (Fig. 5A) making the evaluation of
competition curves diﬃcult. The competition assays for glucose
and inositol were therefore performed at 25 C, which resulted
in a lower rate of GroPIns uptake. Under these conditions,
inositol (10 mM) and glucose (100 lM, 1 mM) were not seen
to compete with the uptake of GroPIns (50 lM) after a
10-min incubation of GLUT2-transfected HeLa cells; in
contrast, 10 mM glucose induced an 20% reduction and
40 mM a complete blockage in GroPIns uptake under these
conditions.
Moreover, phloretin (300 lM), a blocker of the Glut2
glucose transporter that did not have any non-speciﬁc
eﬀect per se in modifying GroPIns binding to cell lysates,
inhibited GroPIns uptake in both GLUT2-transfected cells
and HEK293 cells by 50% (Fig. 5B and C).
Finally, siRNAs speciﬁc for hGlut2 were transfected into
HEK293 cells; these decreased the Glut2 levels by 30–40%
(compared with siCONTROL non-targeting-duplex-treated
cells), without aﬀecting the levels of actin, which was
monitored as a control (Fig. 5E). This loss of hGlut2 caused
an 40% decrease in GroPIns uptake (Fig. 5D), conﬁrming
that this transporter can indeed mediate GroPIns uptake in
cells.4. Discussion
In this study, we demonstrate that in mammalian cells the
human permease Glut2, a member of the MFS of transporters,
can function as a transporter for the phosphoinositide deriva-
tive GroPIns. This mechanism of membrane permeation is
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its pharmacological action when added exogenously to cells.
The only known, speciﬁc GroPIns transporter cloned and
biochemically characterized so far is yeast Gitlp [16,17], which
belongs to the Phosphate:H+ symporter (PHS) subfamily of
the MFS transporters, which includes members from yeast,
fungi and plants, but not from bacteria, animals and other
eukaryotes [27]. Based on both phylogeny and function, the
classiﬁcation of the MFS proteins gives no indications toward
the identiﬁcation of the human Gitlp ortholog, which would
also indicate that this ortholog may have a low homology with
the yeast protein [27]. On the other hand, the phylogenetic tree
shows that the PHS and Sugar Porter (SP) families are related,and the conserved domains of the Gitlp sequence have a high
score relative to the sugar-transporter domain characteristics
of the members of the SP family. It is therefore not surprising
that the human protein that shows the highest homology with
the Gitlp through the PSI-BLAST search is Glut2, a member
of the SP family (Fig. 1).
The hGlut2 protein is characterised by 12 membrane-span-
ning (TMS) helices, comprising seven conserved glycine resi-
dues (crucial for the structures of helices 1, 2, 4, 5, 7, 8, and
10), the QLS motif in helix 7 and the STSIF motif in loop 7
(which participate in substrate recognition), a ﬁve-residue
motif (RXGRR) located between TMS2 and TMS3, and a
similar motif between TMS8 and TMS9 (which is involved
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6794 S. Mariggio` et al. / FEBS Letters 580 (2006) 6789–6796in interactions with negative charges of membrane-lipid head
groups) [24,27,28]. With the exception of the QFS motif, these
are also present in the Gitlp sequence (Fig. 1).
Based on sequence homology, Glut2 was originally identi-
ﬁed as a glucose-like transporter [29]. Glut2 function has been
in part explained with the model of intestinal sugar transport,
where dietary glucose is transported ‘‘uphill’’ by active trans-
porters (such as the Na+/glucose co-transporter, SGLT1) and
then exits across the basolateral membrane of enterocytes
through the facilitative Glut2 transporter [30]. Similar mecha-
nisms have been proposed for glucose transport in hepatic and
pancreatic beta cells, even if Glut2-knock-out mice show
evidence of passive hepatic membrane glucose transport that
is Glut2-independent [31].
More recently, however, Glut2 has been shown to have a
much higher apparent aﬃnity for glucosamine (a naturally
occurring sugar that is necessary for the synthesis of proteogly-
cans) than for glucose (Km = 0.8 ± 0.1 mM versus 17–
20 mM, respectively) [26]. Despite this, the aﬃnity of Glut2
for glucosamine remains in a relatively non-physiological
[26,32], low millimolar range, suggesting that the endogenous
ligand(s) of this transporter remains to be deﬁned.
This is further supported by the data presented in this study,
where we have deﬁned a 10-fold higher apparent aﬃnity of
Glut2 for GroPIns (Km = 80 lM), with respect to the data
reported in oocytes for glucosamine [26].
According to our observations, Glut2 transports in a
competitive manner both positively (glucosamine) and nega-
tively (GroPIns) charged compounds, though the mechanism
involved remains to be clariﬁed. A similar competition by
diﬀerently charged compounds has been reported in the case
of Gitlp in yeast, where the transport of GroPIns is partially
competed by zwitterionic compounds, such as glycerophos-
phocholine and glycerophosphoethanolamine [16].
This characterization of Glut2 as a mammalian ortholog of
Gitlp is also compatible with the cellular concentrations of
GroPIns [6], and the lack of competition by physiological
concentrations of glucose or glucosamine clearly point to the
speciﬁcity of Glut2-mediated GroPIns transport. In line with
these results, the downregulation of Glut2 expression by siR-
NAs also signiﬁcantly decreased GroPIns uptake (Fig. 5D).
In addition, the features of Glut2-mediated GroPIns cellular
uptake are in line with those of the glucose uptake that is
S. Mariggio` et al. / FEBS Letters 580 (2006) 6789–6796 6795mediated by Glutl. Thus, this uptake is rapid and shows a time
course that is similar to that reported for 3-O-methyl-D-glu-
cose uptake into MIN6 cells (mouse insulin-secreting clonal
b-cells, expressing the Glut2 and Glutl glucose transporters),
which has been shown to be rapid and to reach 80% equilib-
rium within 1 min [33].
Of note, the association of radiolabeled GroPIns with intact
cells could derive not only from the uptake of this compound
but also in part from its binding to membranes. This possibil-
ity was analysed, and the net transport was resolved based on a
clear increase in GroPIns uptake in intact cells versus perme-
abilized cells, and also on the pronounced increase of GroPIns
uptake seen upon Glut2 over-expression in intact cells (Fig. 4).
In addition, this increased transport was reduced by the inhib-
itor phloretin and, more important, by the downregulation of
the Glut2 expression using siRNAs, further supporting the
speciﬁcity of Glut2 for GroPIns uptake.
Altogether, these data are in line with the molecular identi-
ﬁcation of Glut2 as one of the proteins involved in GroPIns
transport in mammalian cells. It cannot be concluded,
however, that Glut2 is the only GroPIns transporter in mammals,
since Glut2 is not ubiquitously expressed, but is instead
predominantly present in liver, kidney and small intestine
[29]. This indicates that either phosphoinositide/GroPIns
metabolism is prevalent in these speciﬁc tissues, or that, most
probably, other proteins have a transporter function in tissues
where Glut2 is not expressed. That this is indeed the case is
shown by the levels of GroPIns uptake revealed in cells that
do not expressed Glut2, such as, for example, HeLa cells (cer-
vix adenocarcinoma cells) (Fig. 2C) and Swiss 3T3 ﬁbroblasts
[18]. In these cases, this uptake can reasonably be assigned to a
Glut2-independent mechanism. Instead, the parallel decrease
in Glut2 expression and GroPIns uptake observed in kidney
cells (HEK293, Fig. 5D), strengthen the conclusion that when
endogenously expressed, Glut2 is the speciﬁc GroPIns trans-
porter.
Previous studies have discussed the relevance of transmem-
brane GroPIns permeability for fully deﬁning the GroPIns
metabolic pathways and for exploiting its pharmacological
potential. For the former, GroPIns has been detected in both
the intracellular and extracellular spaces [5,19], and ecto-
enzymes (e.g. glycerophosphodiesterase 1) that can speciﬁcally
metabolize GroPIns to glycerol and inositol monophosphate
have indeed been characterized [20].
As already mentioned, GroPIns is biologically active when
administered exogenously to cells, pointing to the potential
pharmacological exploitation of this compound and its
derivatives. Indeed, when exposed to micromolar concentra-
tions of GroPIns, melanoma and breast carcinoma cells have
a signiﬁcantly reduced ability to invade the extracellular matrix
[3]. This process requires the modulation of several cell func-
tions, including cell attachment and motility, and the interac-
tion, digestion and penetration of the extracellular matrix
[34]. Although not yet fully elucidated, the regulation of these
processes involves activation of diﬀerent signalling pathways
and of the actin machinery, indicating that the action of
GroPIns occurs after it has permeated into the cell. To date,
GroPIns has been shown to activate the small GTPase Rac in
ﬁbroblasts (but not to aﬀect actin organization [2]), and its
mechanism of action in tumor cells remains under investigation.
Based on these ﬁndings, GroPIns, and more in general,
the glycerophosphoinositols, have the desired characteristics(small, naturally occurring, non-toxic, and water-soluble
molecules) for their exploitation in the development and appli-
cation of potential antiproliferative therapies. Our present
characterization of the permeation mechanism responsible
for the transport of GroPIns across the cell membrane clearly
further promotes their therapeutical potential and interest.
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